Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Eikelboom

Showing results (1-10 of 199) with videos related to

Pageof 20
Sort By:
The Lancet. Haematology|October 22, 2020
Mortality benefits of thromboprophylaxisJohn Eikelboom
ACP Journal Club|March 5, 2003
Homocysteine-lowering therapy improved outcomes after percutaneous coronary interventionJohn Eikelboom
Clinical Advances in Hematology & Oncology : H&O|May 27, 2006
Aspirin resistance: does it exist and is it an important clinical problem?John Eikelboom
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
The reemergence of aspirin for the prevention of venous thromboembolismJohn Eikelboom
ACP Journal Club|May 3, 2003
Review: MTHFR TT genotype increases risk for coronary heart diseaseJohn Eikelboom
Clinical Advances in Hematology & Oncology : H&O|January 11, 2008
Nonbleeding complications of unfractionated and low-molecular weight heparinsJohn Eikelboom
European Heart Journal|July 13, 2021
Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?Noel Chan, John Eikelboom
The Canadian Journal of Cardiology|January 12, 2024
Restarting Anticoagulation After Major Bleeding in Patients With Atrial FibrillationStephanie Carlin, John Eikelboom
Lancet (London, England)|March 6, 2004
Ximelagatran or warfarin in atrial fibrillation?John Eikelboom, Graeme Hankey
Annals of Internal Medicine|October 5, 2017
HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a first unprovoked VTEPaul Kruger, John Eikelboom
Pageof 20

Showing results (1-10 of 199) with videos related to

Sort By:
Pageof 20
The Lancet. Haematology|October 22, 2020
Mortality benefits of thromboprophylaxisJohn Eikelboom
ACP Journal Club|March 5, 2003
Homocysteine-lowering therapy improved outcomes after percutaneous coronary interventionJohn Eikelboom
Clinical Advances in Hematology & Oncology : H&O|May 27, 2006
Aspirin resistance: does it exist and is it an important clinical problem?John Eikelboom
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
The reemergence of aspirin for the prevention of venous thromboembolismJohn Eikelboom
ACP Journal Club|May 3, 2003
Review: MTHFR TT genotype increases risk for coronary heart diseaseJohn Eikelboom
Clinical Advances in Hematology & Oncology : H&O|January 11, 2008
Nonbleeding complications of unfractionated and low-molecular weight heparinsJohn Eikelboom
European Heart Journal|July 13, 2021
Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?Noel Chan, John Eikelboom
The Canadian Journal of Cardiology|January 12, 2024
Restarting Anticoagulation After Major Bleeding in Patients With Atrial FibrillationStephanie Carlin, John Eikelboom
Lancet (London, England)|March 6, 2004
Ximelagatran or warfarin in atrial fibrillation?John Eikelboom, Graeme Hankey
Annals of Internal Medicine|October 5, 2017
HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a first unprovoked VTEPaul Kruger, John Eikelboom
Pageof 20